SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Frederick Law Olmsted

PatientFrederick Law Olmsted
Date of birth1953-04-26
IdentifiersMRN HR-NI022-SYN; SSN (made up) 000-22-5519
Document date2026-06-02
AuthorNathan Calder, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-week follow-up: results and MRI, diagnosis, and behavioral neurology consultation the same day. [S]

History of Present Illness

Mr. Olmsted is a 73-year-old man evaluated four weeks ago for about two years of worsening memory, who returns with his caregiver for his results and is seen by behavioral neurology on the same day. Since the first visit he has stopped the glass of wine with dinner. He still repeats questions, loses track of letters and plans, and needs reminders for appointments; his caregiver now handles his medicines and bill paying. He has driven only short familiar routes, and once took a wrong turn near home this month. He sleeps well, has no hallucinations, acting out of dreams, falls, or urinary problems, and his mood is low at times when he thinks about leaving his work. The blood tests at the first visit were normal, and the brain MRI two weeks ago showed generalized and mild medial temporal atrophy with minor small-vessel change, without a stroke, tumor, or fluid build-up. [S]

ElementDetail
MemoryRepeats questions; loses track of letters and plans; needs appointment reminders
FunctionCaregiver now manages medicines and bill paying
DrivingShort familiar routes; one wrong turn near home this month
BehaviorMild irritability and apathy; no hallucinations, dream enactment, or wandering
ResultsBlood count, metabolic panel, vitamin B12, folate, and TSH normal; MRI with generalized and mild medial temporal atrophy and Fazekas grade 1 white-matter change

Review of Systems

SystemResultFinding
NeurologicalPositiveMemory loss; no tremor, weakness, gait change, or falls
PsychiatricPositiveLow mood at times about leaving his work; no hallucinations; no thoughts of self-harm
GenitourinaryNegativeNo urgency or incontinence
CardiovascularNegativeNo fainting or palpitations

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Donepezil 5 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morning with breakfastOral route2026-06-02 to 2026-08-04completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-02Body height175cmS
2026-06-02Body weight71.8kgS
2026-06-02Body mass index (BMI) [Ratio]23.4kg/m2S
2026-06-02Systolic blood pressure132mm[Hg]S
2026-06-02Diastolic blood pressure76mm[Hg]S
2026-06-02Heart rate70/minS
2026-06-02Respiratory rate14/minS
2026-06-02Body temperature36.6CelS
2026-06-02Oxygen saturation in Arterial blood by Pulse oximetry97%S

Physical Exam

Vital signs recorded on 2026-06-02; see the Vital Signs section. [S]

SystemFinding
GeneralAlert, courteous, and articulate; repeats one question during the visit
CardiovascularRegular rhythm at 70 per minute; blood pressure 132/76 mmHg
NeurologicalOriented to person and place, not to date; no rest tremor, rigidity, or bradykinesia; normal gait, with no magnetic or shuffling quality

Problems

ProblemClinical statusVerificationCodeProvenance
Mild dementia (major neurocognitive disorder), progressive, amnestic-predominant with executive difficulty, type undetermined; CDR global 1activeconfirmed F03.A0S — Synthetic modern coding of his documented failing memory; the cause is unknown, so the type is left unspecified. Stage and scores are synthetic.
Progressive memory loss over about two years with decline in managing his work and affairs, under evaluation for dementia or mild cognitive impairmentresolvedconfirmed R41.3S — Synthetic presenting concern at the index visit, superseded by the dementia diagnosis at the four-week visit; the failing memory is documented (D).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyMedication review with the AGS Beers Criteria (anticholinergic burden, sedatives, sleeping pills, antipsychotics)Every visitCompleted todayNo medicines on the Beers list; no over-the-counter sleep aids or antihistamines
SurveyNeuropsychiatric symptom screen (NPI-Q)Every visitCompleted todayMild irritability and apathy, unchanged; no hallucinations, delusions, agitation, or wandering
Medication safetyCholinesterase inhibitor tolerability and benefit: heart rate, fainting, nausea, diarrhea, weight, sleep and dreamsEach follow-up on treatmentCompleted todayBaseline before donepezil: heart rate 70, no fainting, weight 71.8 kg; starting 5 mg today
Medication safetyAntipsychotic appropriateness and taper reviewEvery visit if on an antipsychoticNot indicatedNot on an antipsychotic; none is needed
ExaminationVascular risk-factor control (blood pressure, lipids, glucose, smoking)Every visitCompleted todayBlood pressure 132/76 mmHg, above the 130/80 target only in the systolic reading, without treatment; glucose normal four weeks ago; never smoked; lipids not on record, to be drawn at the wellness visit
ExaminationHome safety evaluationAt diagnosis and each follow-upCompleted todayHome safety checklist given to his caregiver; stove use, night lighting, and medicine storage discussed
SurveyCognitive test (MoCA)Annually; every visit if a change is reportedUp to dateMoCA 19 of 30 four weeks ago
SurveyADL (Katz) and IADL (Lawton-Brody)Annually, and at any reported changeUp to dateKatz ADL 6 of 6 and Lawton IADL 5 of 8 four weeks ago
SurveyDementia stage (CDR or FAST)AnnuallyCompleted todayCDR global 1 and FAST stage 4, confirmed by neurology
SurveyDepression screen (PHQ-9)Annually, and at any reported changeUp to datePHQ-9 6 four weeks ago, below 10; no thoughts of self-harm today
ExaminationFall-risk assessment (Timed Up and Go, gait and balance)AnnuallyUp to dateTimed Up and Go 11 seconds four weeks ago; no falls
ExaminationDriving safety (CDR-based)At diagnosis and annuallyCompleted todayCDR 1 with a wrong turn near home: high risk; neurology advises stopping, and he agreed to stop today
Self-managementFirearms, wandering, and financial safetyAt diagnosis and with any changeCompleted todayNo firearms in the home; no wandering, and a medical identification bracelet advised; his caregiver oversees bill paying with his agreement
SurveyCaregiver burden (Zarit Burden Interview) and caregiver needsAt diagnosis, then every 6 to 12 monthsDeferredNot done at the diagnosis visit, a deviation from the protocol: the visit ran long with the diagnosis discussion and consultation, and the questionnaire sent home was not returned. No caregiver crisis followed. Corrective action: the Zarit Burden Interview is scheduled at the three-month visit and then with each six-month review
Self-managementAdvance care planning and goals of careAt diagnosis, then annually and at stage changesDueDiagnosis disclosed today; advance care planning booked for the three-month visit so he can take part while he is able
LaboratoryTSH, vitamin B12, blood count, and metabolic panelAt diagnosis; repeat only with acute cognitive worseningUp to dateNormal four weeks ago, including vitamin B12 410 pg/mL and TSH 1.9
LaboratorySyphilis and HIV testingOnly with risk factors or atypical featuresNot indicatedNo risk factors, no atypical or rapid course, and no neurological signs
ImagingStructural brain MRI, non-contrastOnce at diagnosis; repeat only with an atypical course or focal changeCompleted todayMRI two weeks ago reviewed: generalized atrophy, mild medial temporal atrophy, Fazekas grade 1; no infarct, mass, or hydrocephalus; no repeat planned
LaboratoryAmyloid or tau biomarkers (blood, CSF, or amyloid PET) and APOE genotypeBefore anti-amyloid therapy, or when the result would change careNot indicatedOffered by neurology; he and his caregiver chose not to pursue biomarkers now, because he does not want anti-amyloid infusions and their MRI monitoring, and the result would not change the rest of his care. Can be revisited
ImagingAnti-amyloid antibody therapy with ARIA surveillance MRIOnly if anti-amyloid therapy is startedNot indicatedNot chosen after discussion with neurology
Self-managementLifestyle: aerobic exercise about twice a week, hearing, vision, sleep, social engagementOngoingCompleted todayDaily walks with company; hearing and vision reviewed at the wellness visit; social contact encouraged
ReferralDementia care navigation and caregiver support programAt enrollment, with ongoing supportCompleted todayAlzheimer's Association helpline and education program information given to his caregiver
ReferralBehavioral neurology consultationAt diagnosis, then yearly or with a changeCompleted todaySeen today: mild dementia of undetermined type confirmed; donepezil and driving cessation advised
Self-managementVaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap)Yearly, per the CDC scheduleDueInfluenza vaccine given last autumn; others at the wellness visit

Goal progress:

Guideline basis: Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001); Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology (2010); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025); The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2025); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026)

Follow-up: Three-month dementia review with the donepezil dose decision, the Zarit Burden Interview, and advance care planning. Next scheduled visit 2026-08-04: three-month dementia review: donepezil, safety plan, caregiver burden, and advance care planning. [S]